RT Journal Article
SR Electronic
T1 Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.16.21265043
DO 10.1101/2021.10.16.21265043
A1 Tunesi, Simone
A1 Dû, Damien Le
A1 Gualano, Gina
A1 Millet, Joan-Pau
A1 Skrahin, Aliaksandr
A1 Bothamley, Graham
A1 Casas, Xavier
A1 Goletti, Delia
A1 Lange, Christoph
A1 Musso, Maria
A1 Palmieri, Fabrizio
A1 Pourcher, Valérie
A1 Rioux, Christophe
A1 Skrahina, Alena
A1 Veziris, Nicolas
A1 Viatushka, Dzmitry
A1 Jachym-Fréchet, Mathilde
A1 Guglielmetti, Lorenzo
A1 for the TBnet
A1 the ESGMYC
A1 the French MDR-TB Group
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.16.21265043.abstract
AB Concomitant treatment for chronic hepatitis C virus infection and multidrug-resistant tuberculosis is safe and effective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was provided by the Institutional Review Board of the coordinating centre (Bligny Hospital, Briis-sous-Forges, France) and by other participating centres.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors